Bill > HR5736

This bill, known as the Penicillin Allergy Verification and Evaluation (PAVE) Act, aims to include penicillin allergy verification and evaluation as part of the initial preventive physical examination and annual wellness visit for Medicare beneficiaries. The bill is based on medical research showing that over 90 percent of patients with a self-reported penicillin allergy can actually safely take penicillin after verification testing. Specifically, the legislation will require healthcare providers to identify individuals reporting a penicillin allergy, evaluate whether the reported reaction history is consistent with a true allergic reaction, provide information about the potential health impacts of maintaining an unnecessary penicillin allergy label, and refer patients to an allergy or immunology specialist when appropriate. The bill acknowledges that a penicillin allergy label can lead to poor patient outcomes, including increased hospital stays and higher mortality rates. The provisions will take effect on January 1, 2027, and allow for separate payment for structured penicillin allergy validation services performed during the initial preventive examination or annual wellness visit. The goal is to improve antibiotic stewardship and potentially reduce unnecessary medical complications for seniors.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/5736/all-info